Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an anxiolytic and has a longer half-life compared to other benzodiazepines.
## Primary Indications
* Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure types and anxiety disorders.
## Adult Dosing
**Lennox-Gastaut Syndrome:**
* Initiate at 5 mg twice daily.
* Titrate upwards by 5-10 mg per day every week as needed, not to exceed a maximum daily dose of 20 mg twice daily (40 mg/day).
## Pediatric Dosing
**Lennox-Gastaut Syndrome:**
* **2 to <10 years:**
* Initiate at 5 mg once daily.
* Titrate upwards by 2.5-5 mg every week as needed.
* Maximum daily dose: 10 mg twice daily (20 mg/day).
* **10 years and older:**
* Follow adult dosing recommendations (initiating at 5 mg twice daily, titrating up to a maximum of 20 mg twice daily).
*Note: Dosing for pediatric patients may require further individualization based on weight and response. Close monitoring is essential.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary, though specific guidelines are not well-established.
* **Renal Impairment:** No specific dose adjustments are typically recommended, but caution is advised.
## Contraindications
* Known hypersensitivity to clobazam or any component of the formulation.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Myasthenia gravis.
* Acute narrow-angle glaucoma.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, drooling, fatigue, gait disturbance, lethargy, respiratory infections, irritability, aggression, nausea, vomiting.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions (e.g., excitation, agitation).
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depressant effects, increasing the risk of profound sedation, respiratory depression, and death. Use concurrently only if other alternatives are inadequate and monitor closely.
* **CYP3A4 Inhibitors/Inducers:** Clobazam is a substrate of CYP3A4. Inhibitors may increase clobazam levels, and inducers may decrease them.
* **Antiepileptic Drugs (AEDs):** Monitor for altered efficacy or toxicity of concomitant AEDs. Clobazam can increase levels of certain AEDs (e.g., stiripentol).
## Monitoring
* Monitor for somnolence and sedation, especially during initiation and dose increases.
* Assess for behavioral changes, including suicidal ideation and aggression.
* Evaluate for signs of withdrawal if the medication is discontinued abruptly.
* Monitor seizure frequency and severity.
## Clinical Pearls
* Clobazam should be used as adjunctive therapy for LGS seizures.
* Due to the risk of dependence and withdrawal, abrupt discontinuation should be avoided. Tapering is recommended.
* The long half-life can lead to accumulation, especially in elderly patients or those with impaired hepatic function.
* Patients and caregivers should be advised about the risk of suicidal thoughts and behaviors.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and guidelines for comprehensive details and to ensure patient safety. Dosing may vary based on individual patient factors and local protocols.
